en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank


 
6/2019
vol. 57
 
Share:
Share:
more
 
 
abstract:
Original paper

The level of TGF-b in sera of patients with primary Sjögren’s syndrome

Maria Maślińska
1
,
Agnieszka Paradowska-Gorycka
2
,
Małgorzata Mańczak
3
,
Kinga Kostyra-Grabczak
1
,
Brygida Kwiatkowska
1

1.
Clinic of Early Arthritis, National Institute of Geriatrics, Rheumatology, and Rehabilitation, Warsaw, Poland
2.
Department of Biochemistry and Molecular Biology, National Institute of Geriatrics, Rheumatology, and Rehabilitation, Warsaw, Poland
3.
Department of Gerontology, Public Health, and Didactics, National Institute of Geriatrics, Rheumatology, and Rehabilitation, Warsaw, Poland
Reumatologia 2019; 57, 6: 309-314
Online publish date: 2019/12/31
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Objectives
Tumor growth factor b (TGF-b) is a pleiotropic cytokine which controls autoimmune reactions, cell proliferation, and the organ accumulation of lymphocytes. This cytokine has a protective and anti-inflammatory effect in autoimmune processes, but also has a pro-fibrinous activity. Therefore, its importance in the development of systemic sclerosis has been proven. The role of TGF-b in Sjögren’s syndrome is also a valid direction of research. The aim of the presented study is to evaluate the level of TGF-b in sera of primary Sjögren’s syndrome patients and to investigate possible correlations with autoantibodies, cytokines, and cells in biopsy of minor salivary glands active in the pathogenesis of this syndrome.

Material and methods
Thirty-three primary Sjögren’s syndrome patients were included. Routine laboratory tests and immunological assessment (ANA, anti SS-A, anti SS-B antibodies, rheumatoid factor), ophthalmological assessment with ocular staining scoring, chest X-ray, and high-resolution computed tomography (if necessary) were performed. Serum concentrations of cytokines such as TGF-b, BAFF, APRIL, FLT-3L, LT-a, IL-21, and TNF-a were evaluated using standard ELISA assays. The histopathological evaluation (focus score) and the determination of CD3+, CD4+, CD19+, CD21+, CD35+ cells was performed.

Results
There was no significant correlation between TGF-b and other tested cytokines or autoantibodies, other than TNF-a. A negative correlation (r = –0.472) between TGF-b and TNF-a was found. There were no correlations between TGF-b and: results of ocular examinations, elements of histopathological variables, or lungs changes.

Conclusions
The authors state that: 1) the results may indicate that TGF-b influences the serum TNF-a activity in pSS patients, 2) our findings suggest that TGF-b may be the strongest inhibitor of TNF-a among cytokines involved in pSS pathogenesis, and 3) the results may explain the ineffectiveness of anti-TNF drugs in the treatment of pSS.

keywords:

transforming growth factor, primary Sjögren’s syndrome, tumor necrosis factor a, tumor growth factor b







Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.